Rationale for randomised trials of prostate cancer screening

F. E. Alexander; G. L. Andriole; G. Aus; A. Auvinen; P. Beensterboer; B. G. Blijenberg; R. Bonardi; S. Buys; B. Candas; S. Ciatto; E. D. Crawford; R. Demers; H. J. De Koning; L. Denis; M. A. Dijk; F. Figueiredo; E. P. Gellman; J. Gohagan; M. Hakama; J. Hugosson; W. I. Kirkels; R. Kranse; Th H. Van der Kwast; H. Lilja; L. Maattanen; J. Mandel; A. B. Miller; H. Monteiro; V. Nelen; A. Oberman; A. Paez; P. C. Prorok; D. Reding; J. W.B.W. Rietbergen; D. B. Rose; A. B. Sanchez; F. H. Schroder; E. C. Da Silva; N. Simpson; P. H. Smith; B. Stadaert; U. H. Stenman; L. Teppo; A. Turkes; J. L. Weissfeld; L. Yokochi

doi:10.1016/S0959-8049(98)00379-7

Rationale for randomised trials of prostate cancer screening

F. E. Alexander, G. L. Andriole, G. Aus, A. Auvinen, P. Beensterboer, B. G. Blijenberg, R. Bonardi, S. Buys, B. Candas, S. Ciatto, E. D. Crawford, R. Demers, H. J. De Koning, L. Denis, M. A. Dijk, F. Figueiredo, E. P. Gellman, J. Gohagan, M. Hakama, J. HugossonW. I. Kirkels, R. Kranse, Th H. Van der Kwast, H. Lilja, L. Maattanen, J. Mandel, A. B. Miller, H. Monteiro, V. Nelen, A. Oberman, A. Paez, P. C. Prorok, D. Reding, J. W.B.W. Rietbergen, D. B. Rose, A. B. Sanchez, F. H. Schroder, E. C. Da Silva, N. Simpson, P. H. Smith, B. Stadaert, U. H. Stenman, L. Teppo, A. Turkes, J. L. Weissfeld, L. Yokochi

Research output: Contribution to journal › Review article › peer-review

67 Scopus citations

Abstract

Screening for prostate cancer has been advocated by a number of organisations largely because there is good evidence that administration of the test for prostate specific antigen (PSA) results in the detection of cancers at an early stage. However, the mere fact that a cancer can be detected earlier in its natural history by screening is no guarantee that benefit will follow. Further, screening for prostate cancer can substantially impair the quality of life of those with detected and treated cancer, that would not otherwise have reduced life expectancy. The only established mechanism to evaluate the efficacy of screening is the randomised controlled trial. In this paper we review the trials contributing to our collaboration, the advantages that will flow from them, and the reasons why decisions on the introduction of population-based screening for prostate cancer cannot be made before these trials have come to fruition.

Original language	English
Pages (from-to)	262-271
Number of pages	10
Journal	European Journal of Cancer
Volume	35
Issue number	2
DOIs	https://doi.org/10.1016/S0959-8049(98)00379-7
State	Published - Feb 1999

Keywords

Prostate cancer
Prostate specific antigen (PSA)
Randomised controlled trials
Screening

Access to Document

10.1016/S0959-8049(98)00379-7

Cite this

Alexander, F. E., Andriole, G. L., Aus, G., Auvinen, A., Beensterboer, P., Blijenberg, B. G., Bonardi, R., Buys, S., Candas, B., Ciatto, S., Crawford, E. D., Demers, R., De Koning, H. J., Denis, L., Dijk, M. A., Figueiredo, F., Gellman, E. P., Gohagan, J., Hakama, M., ... Yokochi, L. (1999). Rationale for randomised trials of prostate cancer screening. European Journal of Cancer, 35(2), 262-271. https://doi.org/10.1016/S0959-8049(98)00379-7

@article{0cad50c5d196409084aa5d37b31ebc10,

title = "Rationale for randomised trials of prostate cancer screening",

abstract = "Screening for prostate cancer has been advocated by a number of organisations largely because there is good evidence that administration of the test for prostate specific antigen (PSA) results in the detection of cancers at an early stage. However, the mere fact that a cancer can be detected earlier in its natural history by screening is no guarantee that benefit will follow. Further, screening for prostate cancer can substantially impair the quality of life of those with detected and treated cancer, that would not otherwise have reduced life expectancy. The only established mechanism to evaluate the efficacy of screening is the randomised controlled trial. In this paper we review the trials contributing to our collaboration, the advantages that will flow from them, and the reasons why decisions on the introduction of population-based screening for prostate cancer cannot be made before these trials have come to fruition.",

keywords = "Prostate cancer, Prostate specific antigen (PSA), Randomised controlled trials, Screening",

author = "Alexander, {F. E.} and Andriole, {G. L.} and G. Aus and A. Auvinen and P. Beensterboer and Blijenberg, {B. G.} and R. Bonardi and S. Buys and B. Candas and S. Ciatto and Crawford, {E. D.} and R. Demers and {De Koning}, {H. J.} and L. Denis and Dijk, {M. A.} and F. Figueiredo and Gellman, {E. P.} and J. Gohagan and M. Hakama and J. Hugosson and Kirkels, {W. I.} and R. Kranse and {Van der Kwast}, {Th H.} and H. Lilja and L. Maattanen and J. Mandel and Miller, {A. B.} and H. Monteiro and V. Nelen and A. Oberman and A. Paez and Prorok, {P. C.} and D. Reding and Rietbergen, {J. W.B.W.} and Rose, {D. B.} and Sanchez, {A. B.} and Schroder, {F. H.} and {Da Silva}, {E. C.} and N. Simpson and Smith, {P. H.} and B. Stadaert and Stenman, {U. H.} and L. Teppo and A. Turkes and Weissfeld, {J. L.} and L. Yokochi",

year = "1999",

month = feb,

doi = "10.1016/S0959-8049(98)00379-7",

language = "English",

volume = "35",

pages = "262--271",

journal = "European Journal of Cancer",

issn = "0959-8049",

number = "2",

}

Alexander, FE, Andriole, GL, Aus, G, Auvinen, A, Beensterboer, P, Blijenberg, BG, Bonardi, R, Buys, S, Candas, B, Ciatto, S, Crawford, ED, Demers, R, De Koning, HJ, Denis, L, Dijk, MA, Figueiredo, F, Gellman, EP, Gohagan, J, Hakama, M, Hugosson, J, Kirkels, WI, Kranse, R, Van der Kwast, TH, Lilja, H, Maattanen, L, Mandel, J, Miller, AB, Monteiro, H, Nelen, V, Oberman, A, Paez, A, Prorok, PC, Reding, D, Rietbergen, JWBW, Rose, DB, Sanchez, AB, Schroder, FH, Da Silva, EC, Simpson, N, Smith, PH, Stadaert, B, Stenman, UH, Teppo, L, Turkes, A, Weissfeld, JL & Yokochi, L 1999, 'Rationale for randomised trials of prostate cancer screening', European Journal of Cancer, vol. 35, no. 2, pp. 262-271. https://doi.org/10.1016/S0959-8049(98)00379-7

TY - JOUR

T1 - Rationale for randomised trials of prostate cancer screening

AU - Alexander, F. E.

AU - Andriole, G. L.

AU - Aus, G.

AU - Auvinen, A.

AU - Beensterboer, P.

AU - Blijenberg, B. G.

AU - Bonardi, R.

AU - Buys, S.

AU - Candas, B.

AU - Ciatto, S.

AU - Crawford, E. D.

AU - Demers, R.

AU - De Koning, H. J.

AU - Denis, L.

AU - Dijk, M. A.

AU - Figueiredo, F.

AU - Gellman, E. P.

AU - Gohagan, J.

AU - Hakama, M.

AU - Hugosson, J.

AU - Kirkels, W. I.

AU - Kranse, R.

AU - Van der Kwast, Th H.

AU - Lilja, H.

AU - Maattanen, L.

AU - Mandel, J.

AU - Miller, A. B.

AU - Monteiro, H.

AU - Nelen, V.

AU - Oberman, A.

AU - Paez, A.

AU - Prorok, P. C.

AU - Reding, D.

AU - Rietbergen, J. W.B.W.

AU - Rose, D. B.

AU - Sanchez, A. B.

AU - Schroder, F. H.

AU - Da Silva, E. C.

AU - Simpson, N.

AU - Smith, P. H.

AU - Stadaert, B.

AU - Stenman, U. H.

AU - Teppo, L.

AU - Turkes, A.

AU - Weissfeld, J. L.

AU - Yokochi, L.

PY - 1999/2

Y1 - 1999/2

N2 - Screening for prostate cancer has been advocated by a number of organisations largely because there is good evidence that administration of the test for prostate specific antigen (PSA) results in the detection of cancers at an early stage. However, the mere fact that a cancer can be detected earlier in its natural history by screening is no guarantee that benefit will follow. Further, screening for prostate cancer can substantially impair the quality of life of those with detected and treated cancer, that would not otherwise have reduced life expectancy. The only established mechanism to evaluate the efficacy of screening is the randomised controlled trial. In this paper we review the trials contributing to our collaboration, the advantages that will flow from them, and the reasons why decisions on the introduction of population-based screening for prostate cancer cannot be made before these trials have come to fruition.

AB - Screening for prostate cancer has been advocated by a number of organisations largely because there is good evidence that administration of the test for prostate specific antigen (PSA) results in the detection of cancers at an early stage. However, the mere fact that a cancer can be detected earlier in its natural history by screening is no guarantee that benefit will follow. Further, screening for prostate cancer can substantially impair the quality of life of those with detected and treated cancer, that would not otherwise have reduced life expectancy. The only established mechanism to evaluate the efficacy of screening is the randomised controlled trial. In this paper we review the trials contributing to our collaboration, the advantages that will flow from them, and the reasons why decisions on the introduction of population-based screening for prostate cancer cannot be made before these trials have come to fruition.

KW - Prostate cancer

KW - Prostate specific antigen (PSA)

KW - Randomised controlled trials

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=0033083961&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(98)00379-7

DO - 10.1016/S0959-8049(98)00379-7

M3 - Review article

C2 - 10448269

AN - SCOPUS:0033083961

SN - 0959-8049

VL - 35

SP - 262

EP - 271

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 2

ER -

Rationale for randomised trials of prostate cancer screening

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this